Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00969137 · ClinicalTrials.gov registry record · Phase 1
Sensitivity to Intravenous Nicotine: Genetic Moderators
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 213
- Enrollment target
NCT00969137 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 213 participants.
The verdict
NCT00969137, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 213 participants
- Enrollment target
Study Summary
To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.
Interventions
- DRUG Nicotine
- DRUG saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2009-06-02 |
| Est. Completion | 2016-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00969137
The ClinicalTrials.gov registry entry for NCT00969137 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotine is the first listed.
NCT00969137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00969137 about?
NCT00969137 is a clinical study titled "Sensitivity to Intravenous Nicotine: Genetic Moderators". To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" an...
What is the current status of trial NCT00969137?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2009-06-02. Estimated completion is 2016-06-01.
What interventions are being tested in trial NCT00969137?
The interventions under investigation include: Nicotine (DRUG), saline (DRUG).
Who is sponsoring clinical trial NCT00969137?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.